HomeBUSINESS
BUSINESS

Repatha Label Updated in Japan to Add CV Risk Reduction Data
(Jul.11.2018)

Amgen Astellas BioPharma said on July 10 that they have updated the label for their hypercholesterolemia treatment Repatha (evolocumab) in Japan by adding cardiovascular risk reduction data from a key global PIII study dubbed FOURIER ...
(LOG IN FOR FULL STORY)